New Licensing Deal is a BIG Deal: OSRH announced a non-binding licensing term sheet with BCME (with new increasing probability of execution) for development of VXM01. The deal carries implications for strong 2026+ cashflow and longer-term prospects. The Company owns developmental platform technologies that address cancer immunotherapy and degenerative disease markets plus a largely de-risked, revenue-producing medical device distribution/4th party logistics (4PL) business and a diabetes medical device developer (currently in trials).
